Bookmark
Forward
QuickView for Lamivudine (compound)
PubChem
| Name: | Lamivudine |
|---|---|
| PubChem Compound ID: | 3877 |
| Description: | A reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease. |
| Molecular formula: | C8H11N3O3S |
| Molecular weight: | 229.257 g/mol |
| Synonyms: |
2'-deoxy-3'-thiacytidine; NSC620753; BCH-189; NCI60_006139
|
DrugBank
Identification
| Name: | Lamivudine |
|---|---|
| Name (isomeric): | DB00709 |
| Drug Type: | small molecule |
| Description: | A reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease. |
| Synonyms: |
Lamivudine [Usan:Ban:Inn]
|
| Brand: | Hepitec, Epivir, 3TC, Heptovir, Epivir-HBV, Zeffix |
| Brand name mixture: | Combivir(Lamivudine + Zidovudine), Trizivir(Abacavir Sulfate + Lamivudine + Zidovudine), Kivexa(Abacavir Sulfate + Lamivudine), Epzicom(Abacavir Sulfate + Lamivudine) |
| Category: | Anti-HIV Agents, Nucleoside and Nucleotide Reverse Transcriptase Inhibitors, Reverse Transcriptase Inhibitors |
| CAS number: | 134678-17-4 |
Pharmacology
| Indication: | For the treatment of HIV infection and chronic hepatitis B (HBV). |
|---|---|
| Pharmacology: |
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV). Lamivudine is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of ...
show more » |
| Mechanism of Action: | Lamivudine is a synthetic nucleoside analogue and is phosphorylated intracellularly to its active 5'-triphosphate metabolite, lamivudine triphosphate (L-TP). This nucleoside analogue is incorporated into viral DNA by HIV reverse transcriptase and HBV polymerase, resulting in DNA chain termination. |
| Absorption: | Lamivudine was rapidly absorbed after oral administration in HIV-infected patients. Absolute bioavailability in adults is 86% ± 16% for the tablet and 87% ± 13% for the oral solution. |
| Protein binding: | 36% |
| Biotransformation: | The only detected metabolite of lamivudine is trans-sulfoxide. |
| Route of elimination: | The primary routes of elimination of abacavir are metabolism by alcohol dehydrogenase to form the 5′-carboxylic acid and glucuronyl transferase to form the 5′-glucuronide. Lamivudine is excreted in human breast milk and into the milk of lactating rats. |
| Half Life: | 5 to 7 hours |
| Clearance: | Renal cl=280.4 +/- 75.2 mL/min [HIV-infected patients given a single IV doses ranging from 0.25 to 8 mg/kg] |
| Affected organisms: | Hepatitis B virus||Human Immunodeficiency Virus |
Interactions
| Food interaction: |
| ||||||
|---|---|---|---|---|---|---|---|
| Drug interaction: |
|
Targets
Transporters
